Alpha IVF Group strengthens presence in China with second sales representative office.
• Guangzhou sales representative office commences operations on 6 January 2025 to further amplify patient growth from China
KUALA LUMPUR, Malaysia, 7 January 2025 – Leading fertility care specialist, Alpha IVF Group Berhad (“Alpha IVF Group”, “the Group”, “阿儿法国际辅助生殖集团”, Bloomberg: ALPHA MK, Bursa Ticker: 0303) commenced operations at its second sales representative office in Guangzhou, Guangdong province, China, following the successful opening of its first sales office in Shanghai on 4th September last year.
The Shanghai sales office has demonstrated immense potential for a localized approach. Within just three months of operations, the number of Oocyte Pick Ups (OPU’s) from China patients to the Group’s Kuala Lumpur centre (Alpha KL) rose 33% to 120, compared to 90 in the first quarter ended 31 August 2024 (1Q25), underscoring the effectiveness of the local sales office in enhancing patient channeling.
Building on this momentum, the newly established sales office in Guangzhou, which officially began operations on 6 January 2025, aims to further amplify the number of OPU’s from China. With a population of 15 million, Guangzhou is now another key city, in addition to Alpha IVF Group’s sales office in Shanghai, to unlock opportunities in the Chinese market.
“The opening of our Guangzhou sales office represents another step forward in our strategy to make fertility care more accessible to families across China. With Guangzhou now opened, we are ready to expand our reach even further, creating more opportunities and partnerships for Chinese patients to experience high clinical pregnancy success rates through our comprehensive and advanced IVF technologies that Alpha IVF Group is known for.”
Dato’ Dr. Colin Lee Soon Soo (拿督 李顺树医生)
Group Managing Director, Alpha IVF Group
China continues to be a pivotal growth market for the Alpha IVF Group, driven by the ever-rising demand for fertility treatment services, which continues to play an increasingly significant role in our foreign patients’ revenue. The establishment of this new sales office reaffirms the Group’s commitment to providing accessible pathways for families in China seeking world-class fertility care.
Similar to the Shanghai sales office, the Guangzhou sales office will act as a strategic platform for the Group to introduce its advanced fertility services to residents in China. These advanced fertility services include Preimplantation Genetic Testing for Aneuploidies (PGTA) and In-vitro Activation (IVA) to support older couples in achieving pregnancy. These advanced services are not easily accessible to patients within China.
